IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (API-01-20-US)

In Re Application of:)
Parrington, et al) Examiner: Sean E. Aeder
Serial No.: 10/510, 677	,)
) Group Art Unit: 1642
Filing Date: 09 APRIL 2003)
Title: MODIFIED CEA NUCLEIC ACID AND	<i>)</i>)
EXPRESSION VECTORS	ì

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Submitted via EFS-Web

To the Examiner:

Applicants respectfully submit this Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

CITED REFERENCES

U.S. Patents

- 20030082150A1
- 20030113919A1
- 20040009185A1
- 20040019195A1
- 20040091995A1
- 20070048860A1
- 4,603,112
- 4,722,848
- 4,769,330
- 4,882,278
- 4,956,281
- 5,093,258
- 5,110,587
- 5,122,599
- 5,141,742
- 5,155,020
- 5,174,993
- 5,204,243
- 5,225,336
- 5,274,087
- 5,279,833
- 5,283,185
- 5,342,774 5,348,887
- 5,364,773
- 5,378,457
- 5,405,940
- 5,453,364
- 5,462,871
- 5,494,807 5,504,005
- 5,505,941
- 5,527,928
- 5,547,853
- 5,554,506
- 5,554,724
- 5,571,710
- 5,585,461
- 5,589,466
- 5,591,430
- 5,612,216
- 5,631,010

- 5,651,981
- 5,686,068
- 5,695,994
- 5,698,530
- 5,703,055
- 5,707,618
- 5,738,852
- 5,739,026
- 5,747,028
- 5,756,103
- 5,762,938
- 5,789,245
- 5,792,462
- 5,833,975
- 5,843,448
- 5,843,723
- 5,843,761
- 5,851,523
- 5,858,776
- 5,871,727
- 5,919,676
- 5,932,210
- 5,942,235
- 5,965,535
- 5,990,091
- 5,994,132
- 5,994,136
- 6,001, 349
- 6,013,516
- 6,019,987
- 6,022,958
- 6,025,474
- 6,045,802
- 6,057,158
- 6,071,716
- 6,171,855
- 6,224,879 6,235,522
- 6,277,633
- 6,319,496 6,353,089
- 6,548,068
- 6,531,451
- 6,555,107
- 6,566,093
- 6,699,475

6,756,038

6,893,869

6,969,609

7,084,239

7,211,432

Non-U.S. Patent Documents

WO 91/11194A1

WO 96/11279A2

WO 97/15597A1

WO 98/04728A1

WO 98/29556A1

WO 99/43839A1

WO 01/30382A1

WO 03/080800A2

WO 03/085087A3

Other Documents:

BEI, et al. 1994. J. Immunotherapy with Emphasis on Tumor Immunology, 16(4): 275-282

BOON, et al. 1994. Ann. Rev. Immunol. 12:337-365

CHAMBERLAIN, 1996. Cancer Res. 56: 2832-2836

CONRY, et al. 1999, Clin. Cancer Res. 5: 2330-2337

GenBank Accession No. X60958 (July 18, 1991)

GenBank Accession No. M27533 (Sept. 8, 1989)

GenBank Accession No. X52264 (Aug. 28, 1989)

GenBank Accession No. J03132 (March 25, 1988)

GenBank Accession No. X53526 (June 18, 1990)

GenBank Accession No. Y00636 (Aug. 31, 1987)

GenBank Accession No. U02567 (Oct. 18, 1993)

GenBank Accession No. U03397 (Nov. 10, 1993)

HODGE, et al. 1995. Cancer Res. 55: 3598-3603

HODGE, et al. 1999. Cancer Research, 59(22): 5800-5807

HORIG, et al. 2000. Cancer Immunol. Innumother, 49: 504-514

HUARTE, et al. 2002. Clin. Cancer Res. 8(7): 2336-2344

MARSHALL, et al. 2000, J. Clinical Oncol. 18: 3964-3973

MOINGEON, P. 2001. Vaccine. 19 (11-12): 1305-1326

OERTLI, et al. 2002, Human Gene Therapy, 13: 569-575

SALAZAR, et al. 2000. Int. J. of Cancer, 85(6): 829-838

TARTAGLIA, et al. 1992. Virology. 188: 217-232

TARTAGLIA, et al. 1993. J. Virol. 67: 2370-2375

TARTAGLIA, et al. 2001. Vaccine. 19: 2571-2575

TERSKIKH, et al. 1993. Mol. Immunol. 30(10): 921-927

VON MEHREN, et al. 2000. Clinical Cancer Res. 6: 2219-2228

VON MEHREN, et al. 2001. Clinical Cancer Res. 7: 1181-1191

ZAREMBA, et al. 1997, Cancer Research, 57;4570-4577

Respectfully Submitted,

Date: Sept. 24, 2009 By: /Patrick J. Halloran/

Patrick J. Halloran Reg. No. 41,053

Patrick J. Halloran, Ph.D., J.D. 3141 Muirfield Road Center Valley, PA 18034

Tel: 610-984-4751 Fax: 484-214-0164